Mental health symptoms and awareness of memory problems in mild cognitive impairment
Looks at mental health symptoms and daily life difficulties in people with mild cognitive impairment.
Key facts
- Who runs it
- IRCCS Centro Neurolesi Bonino Pulejo
- Where
- Italy1 site in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- Mild Cognitive Impairment and Psychopathology
- Status
- Not yet recruiting
- People taking part
- 118 people, planned
- Started
- 12 Jan 2026
- Expected to end
- 12 Jan 2027
- Type of study
- Observational
- Record updated
- 22 January 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with Mild Cognitive Impairment (MCI), a memory and thinking decline greater than normal aging. It studies mood and mental health problems, awareness of the decline, and social and work life.
- Age
- 50 to 72 years
- Sex
- All sexes
- Disease stage
- Diagnosis of Mild Cognitive Impairment (MCI), referred to the Neuropsychology clinic for a first evaluation or for follow-up.
- Earlier treatment
- Medicines that can strongly affect thinking (such as sedatives or high-dose antipsychotics) must be stable at the time of the assessment.
Main reasons for not taking part
- Other brain or nerve diseases, such as recent stroke, severe brain injury, epilepsy or multiple sclerosis
- Serious mental illness that is not stable, such as schizophrenia, active bipolar disorder or untreated severe depression
- Severe sight or hearing problems that are not corrected
- Behavioral, psychiatric or sensory problems that would make tests or questionnaires hard to complete
- End-stage illness, including cancer, or other conditions that interfere with the assessments
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- Age between 50 and 72 years
- Diagnosis of Mild Cognitive Impairment (MCI), with referral to the Neuropsychology clinic for an initial evaluation or for clinical monitoring
- Absence of behavioral, psychiatric, or sensory disorders that could significantly compromise the performance of cognitive tests or the completion of questionnaires
Who cannot take part
- Use of medications with significant potential cognitive impact (e.g., sedatives, high-dose antipsychotics) not stabilized at the time of the assessment
- Neurological disorders other than MCI, such as recent stroke, severe traumatic brain injury, epilepsy, multiple sclerosis, or other atypical neurodegenerative diseases
- Major psychiatric comorbidities not stabilized at the time of the assessment (e.g., schizophrenia, bipolar disorder in an active phase, untreated severe depression)
- Terminal-stage internal or oncological diseases, or other medical conditions that significantly interfere with the assessment procedures
- Severe uncorrected sensory deficits (visual or hearing) capable of compromising the validity of cognitive and functional assessments
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 50 and 72 years old?
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Mild Cognitive Impairment (MCI) is a condition characterized by cognitive deterioration greater than what is expected from normal aging, representing an important risk factor for the development of dementia. Early assessment of cognitive functions is therefore essential for promptly identifying any signs of decline. In addition to cognitive aspects, it is equally important to consider the possible psychopathological profile of patients, as such disorders can significantly influence the progression of the disease, quality of life, and the ability to manage daily activities. This protocol aims to explore the presence of psychopathological disorders in patients with MCI, with particular attention to their impact on awareness of cognitive deficits (anosognosia) and on the subjective perception of difficulties in daily life, especially in social and work contexts. The study seeks to outline a comprehensive picture of the psychopathological profile in patients with MCI, facilitating the identification of targeted and personalized interventions capable of improving clinical management and the overall well-being of the individual.
The group in the trial
- MCI
Patients diagnosed with Mild Cognitive Impairment
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Mild Cognitive Impairment and Psychopathology: Effects on Awareness, Social Life, and Work. Cross-sectional Observational Study
- Plain-language title
- Mental health symptoms and awareness of memory problems in mild cognitive impairmentGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Fit questions
- Built from NCT07358962, who can take part
- Record updated
- 22 January 2026